A Phase 4, Randomized, Double-Blind Study With a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects With Relapsing-Remitting Multiple Sclerosis Treated With Tecfidera® (Dimethyl Fumarate) Delayed-Release Capsules

Trial Profile

A Phase 4, Randomized, Double-Blind Study With a Safety Extension Period to Evaluate the Effect of Aspirin on Flushing Events in Subjects With Relapsing-Remitting Multiple Sclerosis Treated With Tecfidera® (Dimethyl Fumarate) Delayed-Release Capsules

Completed
Phase of Trial: Phase IV

Latest Information Update: 30 Dec 2016

At a glance

  • Drugs Aspirin (Primary) ; Dimethyl fumarate (Primary)
  • Indications Flushing; Multiple sclerosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ASSURE
  • Sponsors Biogen
  • Most Recent Events

    • 04 Apr 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 12 Jun 2015 Planned End Date changed from 1 Apr 2016 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
    • 12 Jun 2015 Planned primary completion date changed from 1 May 2015 to 1 Feb 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top